Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 13/20 | 0.65 |
| ▸ | MMP9 | P14780 | 13/20 | 0.60 |
| ▸ | MMP12 | P39900 | 12/20 | 0.60 |
| ▸ | MMP2 | P08253 | 11/20 | 0.60 |
| ▸ | MMP14 | P50281 | 11/20 | 0.60 |
| ▸ | MMP15 | P51511 | 11/20 | 0.60 |
| ▸ | MMP16 | P51512 | 11/20 | 0.60 |
| ▸ | MMP26 | Q9NRE1 | 10/20 | 0.60 |
| ▸ | MMP7 | P09237 | 8/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 4/20 | 0.47 |
| ▸ | MMP3 | P08254 | 3/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439966 | 1.00 | MMP1 (0.65) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL14427220 | 0.90 | AKR1C3 (0.53) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL14427157 | 0.86 | MMP12 (0.77) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL14427161 | 0.85 | MMP1 (0.76) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL14427230 | 0.83 | MMP1 (0.66) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL14427180 | 0.83 | MMP1 (0.66) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL14427189 | 0.83 | MMP1 (0.69) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL12955747 | 0.83 | MMP1 (0.66) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL14427250 | 0.83 | MMP1 (0.72) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL14427228 | 0.83 | MMP1 (0.66) | MMP1MMP9MMP12MMP2MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-30 | — | — | US | claimed |
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | MMP9, MMP2, MMP3 | MMP1 8/4885MMP9 1/4885MMP12 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.